The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

TitleThe 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Publication TypeJournal Article
Year of Publication2021
AuthorsHolstein, SA, Bahlis, N, P Bergsagel, L, Bhutani, M, Bolli, N, Brownstein, C, Demolis, P, Foureau, D, Gay, F, Ghobrial, IM, Gormley, N, Hillengass, J, Kaiser, M, Maus, MV, J Melenhorst, J, Merz, M, Dwyer, MO, Paiva, B, Pasquini, MC, Shah, N, Wong, SW, Usmani, SZ, McCarthy, PL
JournalTransplant Cell Ther
Volume27
Issue10
Pagination807-816
Date Published2021 10
ISSN2666-6367
KeywordsBone Marrow, Diterpenes, High-Throughput Nucleotide Sequencing, Humans, Multiple Myeloma, Neoplasm, Residual
Abstract

The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.
DOI10.1016/j.jtct.2021.05.027
Alternate JournalTransplant Cell Ther
PubMed ID34107340
PubMed Central IDPMC8478786
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
U24 HL138660 / HL / NHLBI NIH HHS / United States